Autolus Therapeutics plc (AUTL)
| Market Cap | 415.18M -10.9% |
| Revenue (ttm) | 92.62M +927.9% |
| Net Income | -288.97M |
| EPS | -1.09 |
| Shares Out | 266.14M |
| PE Ratio | n/a |
| Forward PE | n/a |
| Dividend | n/a |
| Ex-Dividend Date | n/a |
| Volume | 1,019,732 |
| Open | 1.570 |
| Previous Close | 1.560 |
| Day's Range | 1.520 - 1.640 |
| 52-Week Range | 1.175 - 2.700 |
| Beta | 2.01 |
| Analysts | Strong Buy |
| Price Target | 8.71 (+458.33%) |
| Earnings Date | May 14, 2026 |
About AUTL
Autolus Therapeutics plc, a clinical-stage biopharmaceutical company, develops T cell therapies for the treatment of cancer and autoimmune diseases in the United Kingdom and internationally. The company offers AUCATZYL, a gene therapy product consisting of autologous T cells that are transduced with a lentiviral vector to express a novel anti-CD19 chimeric antigen receptor. It also develops obe-cel, which is in phase 1 to treat systemic lupus erythematosus, progressive multiple sclerosis, B-NHL and CLL, and CNS lymphoma; obe-cel, which is in ph... [Read more]
Financial Performance
In 2025, Autolus Therapeutics's revenue was $75.39 million, an increase of 644.94% compared to the previous year's $10.12 million. Losses were -$287.53 million, 30.3% more than in 2024.
Financial StatementsAnalyst Summary
According to 10 analysts, the average rating for AUTL stock is "Strong Buy." The 12-month stock price target is $8.71, which is an increase of 458.33% from the latest price.
News
Autolus Therapeutics Receives Prix Galien UK Award
LONDON and GAITHERSBURG, Md., June 12, 2026 (GLOBE NEWSWIRE) -- Autolus Therapeutics plc (Nasdaq: AUTL), a commercial-stage biopharmaceutical company developing, manufacturing and delivering next-gene...
Autolus Therapeutics Transcript: Jefferies Global Healthcare Conference 2026
Strong U.S. launch and expanding adoption of the lead CAR-T product are driving revenue growth, with real-world data confirming high efficacy and safety. International expansion is underway, and margin positivity was achieved ahead of schedule, while clinical programs in pediatric, frontline, and autoimmune indications continue to advance.
Autolus Therapeutics to Participate in Upcoming Investor Conferences
LONDON and GAITHERSBURG, Md., May 27, 2026 (GLOBE NEWSWIRE) -- Autolus Therapeutics plc (Nasdaq: AUTL), a commercial-stage biopharmaceutical company developing, manufacturing and delivering next-gener...
Autolus Therapeutics to Present Clinical Data Update at the American Society of Clinical Oncology Annual Meeting 2026
LONDON and GAITHERSBURG, Md., May 21, 2026 (GLOBE NEWSWIRE) -- Autolus Therapeutics plc (Nasdaq: AUTL), a commercial-stage biopharmaceutical company developing, manufacturing and delivering next-gener...
Autolus Therapeutics Slides: Corporate presentation
Autolus Therapeutics has posted slides in relation to its latest quarterly earnings report, which was published on May 21, 2026.
Autolus Therapeutics price target raised to $10 from $9 at H.C. Wainwright
H.C. Wainwright raised the firm’s price target on Autolus Therapeutics (AUTL) to $10 from $9 and keeps a Buy rating on the shares post the Q1 report. The firm says…
Autolus Therapeutics reports Q1 EPS (27c), consensus (26c)
Reports Q1 revenue $26.22M, consensus $26.13M. “In the first quarter, Autolus continued to expand market share for AUCATZYL in the US based on strong physician experience in adult ALL, and…
Autolus Therapeutics backs FY26 revenue view $120M-$135M, consensus $129.39M
The company said, “Autolus reiterates its full year 2026 outlook for AUCATZYL net product revenue of between $120 million to $135 million, up from $74 million in 2025, as well…
Autolus Therapeutics Earnings Call Transcript: Q1 2026
Q1 2026 saw strong revenue growth, first positive gross margin, and expanding U.S. and U.K. market penetration. Guidance for 2026 revenue is unchanged, with operational improvements and clinical pipeline progress supporting long-term growth and profitability targets.
Autolus Therapeutics Earnings release: Q1 2026
Autolus Therapeutics released its Q1 2026 earnings on May 14, 2026, summarizing the period's financial results.
Autolus Therapeutics Quarterly report: Q1 2026
Autolus Therapeutics has published its Q1 2026 quarterly earnings report on May 14, 2026.
Autolus Therapeutics Slides: Q1 2026
Autolus Therapeutics has posted slides in relation to its Q1 2026 quarterly earnings report, which was published on May 14, 2026.
Autolus Therapeutics Reports First Quarter 2026 Financial Results and Business Updates
AUCATZYL® (obecabtagene autoleucel; obe-cel) net product revenue of $26.2 million for the first quarter of 2026, reflecting strong launches in the US and most recently the UK Company achieves positive...
Autolus Therapeutics to Report First Quarter 2026 Financial Results and Host Conference Call on May 14, 2026
LONDON and GAITHERSBURG, Md., May 05, 2026 (GLOBE NEWSWIRE) -- Autolus Therapeutics plc (Nasdaq: AUTL), a commercial stage biopharmaceutical company developing, manufacturing and delivering next-gener...
Autolus Therapeutics to reduce workforce by approximately 13%
Autolus Therapeutics (AUTL) announced a strategic initiative and plan to improve operational efficiency and reduce operating expenses. As part of this initiative, the company is implementing a reducti...
Autolus Therapeutics Announces Initiative to Support Operational Efficiency and Cost Reduction
Initiative focused on driving gross profit margin and path to profitability for the ALL business Company will reduce headcount by approximately 13% while doubling manufacturing of products for commerc...
Autolus Therapeutics Announces Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)
LONDON and GAITHERSBURG, Md., April 21, 2026 (GLOBE NEWSWIRE) -- Autolus Therapeutics plc (Nasdaq: AUTL), a commercial-stage biopharmaceutical company developing, manufacturing and delivering next-gen...
Autolus Therapeutics Transcript: 25th Annual Needham Virtual Healthcare Conference
AUCATZYL (obe-cel) demonstrates strong efficacy and safety in relapsed/refractory ALL, with expanding U.S. and U.K. market presence and robust real-world results. Ongoing trials target broader patient groups, including frontline and pediatric populations, while margin improvements and scalable manufacturing support future growth.
Autolus Therapeutics Registration statement: Registration filing
Autolus Therapeutics filed a registration statement on April 13, 2026, providing details about a securities offering with the SEC.
Autolus Therapeutics Registration statement: Registration filing
Autolus Therapeutics filed a registration statement on April 13, 2026, providing details about a securities offering with the SEC.
Autolus Therapeutics Slides: Corporate presentation
Autolus Therapeutics has posted slides in relation to its latest quarterly earnings report, which was published on April 13, 2026.
Autolus Therapeutics files to sell 54.58M American Depositary Shares for holders
06:02 EDT Autolus Therapeutics (AUTL) files to sell 54.58M American Depositary Shares for holders
Autolus Therapeutics files $150M mixed securities shelf
06:03 EDT Autolus Therapeutics (AUTL) files $150M mixed securities shelf
Autolus Therapeutics Transcript: Status update
Obe-cel CAR T-cell therapy demonstrates high efficacy and a favorable safety profile in both clinical trials and real-world settings for adult and pediatric ALL, enabling broader patient access and reducing reliance on transplantation. Ongoing studies aim to expand its use to frontline consolidation, with promising early results and increasing adoption across treatment centers.
Autolus Therapeutics Slides: Status update
Autolus Therapeutics has posted slides in relation to its latest quarterly earnings report, which was published on April 8, 2026.